• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

    56.71 -1.38 (-2.38%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Ionis Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    14 15 Next >
    Stay updated with the stocks that are on the move in today's after-hours session. ↗
    Via Chartmill
    News headline image
    Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment ↗
    Ionis Pharmaceuticals (NASDAQ:IONS) said the U.S. Food and Drug Administration has approved ZANVASTRO as the first and only disease-modifying treatment for Alexander disease, an ultra-rare, progressive... 
    Via MarketBeat
    Ionis Pharmaceuticals (NASDAQ:IONS) Surges After Q2 Earnings Beat Estimates ↗
    Via Chartmill
    Topics Earnings
    News headline image
    ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis to present at upcoming investor conferences
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone ↗
    This biotech stock looks like a great candidate to buy on the admittedly steep dip. 
    Via The Motley Fool
    News headline image
    Breakfast News: A Conversation With Ionis CEO ↗
    Ionis Pharmaceuticals CEO on a major profitability milestone, breakthrough medicines and more. 
    Via The Motley Fool
    Topics ETFs World Trade
    News headline image
    Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗
    Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think. 
    Via The Motley Fool
    News headline image
    Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? ↗
    A drug that didn't meet expectations in a trial is to blame. 
    Via The Motley Fool
    News headline image
    IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law
    From Schall, Brown & Schwartz LLP
    Via Business Wire
    News headline image
    Ionis (IONS) Q2 2026 Earnings Call Transcript ↗
    Revenue hit $268 million with 56% growth, while TRYNGOLZA sales accelerated. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors? ↗
    Insider holdings surged 34% through indirect acquisition, signaling confidence amid company's $8.8 billion valuation and RNA-therapy pipeline advancement. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Ionis Pharmaceuticals Q2 Earnings Call Highlights ↗
    Ionis Pharmaceuticals (NASDAQ:IONS) reported second-quarter revenue growth driven by commercial products and partnered research programs, while highlighting the recent U.S. approval and early launch... 
    Via MarketBeat
    Topics Earnings
    News headline image
    Ionis announces Dr. Frank Bennett, chief scientific officer, to retire
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis reports second quarter 2026 financial results and highlights progress on key programs
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Cathie Wood Just Bet Big on This Biotech Stock ↗
    Ionis Pharmaceuticals' shares are down more than 27% so far this year. What does Cathie Wood see that others are missing? 
    Via The Motley Fool
    Topics ETFs
    News headline image
    Ionis to hold second quarter 2026 financial results webcast
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗
    Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals. 
    Via MarketBeat
    News headline image
    IONS Investor Alert: Levi & Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)
    From Levi & Korsinsky, LLP
    Via Business Wire
    News headline image
    Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    Which stocks are experiencing notable movement on Thursday? ↗
    Via Chartmill
    Let's take a look at the stocks that are in motion in today's session. ↗
    Via Chartmill
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    14 15 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.